Who Owns Biologics by McKesson?

• Parent Company: McKesson Corporation
• Ownership Type: Wholly owned
• Company Type: Publicly Traded
• Stock Ticker: NYSE: MCK

• Founded: 1994
• Founders: McKesson Corporation (internal development)

• Founded: 1833
• Headquarters: Irving, Texas, USA
• Company Type: Publicly Traded
• Stock: NYSE: MCK
• Revenue: approximately $354 billion (FY2025, year ended March 2025)
• Employees: Approximately 51,000

Visit McKesson Corporation website

• Headquarters: Cary, North Carolina, USA
• Manufacturing / Operations: United States

Biologics by McKesson operates within McKesson Corporation's comprehensive healthcare sustainability framework, focusing on patient care excellence, environmental responsibility, and community engagement while maintaining high ethical standards in specialty pharmacy services.

Patient Care Sustainability: Biologics by McKesson demonstrates sustainability through long-term patient care relationships, supporting cancer patients and individuals with rare diseases throughout their treatment journeys. The specialty pharmacy model emphasizes continuity of care, medication adherence support, and personalized patient education that contributes to better health outcomes and reduced healthcare system costs.

Environmental Compliance: As part of McKesson's broader environmental initiatives, Biologics by McKesson adheres to strict environmental compliance in pharmaceutical handling, storage, and distribution. The company implements energy-efficient facilities, proper waste disposal for pharmaceutical products, and sustainable packaging solutions that minimize environmental impact while maintaining medication safety and integrity.

Community Engagement: Biologics by McKesson actively participates in McKesson's community impact initiatives, including employee volunteer programs, GivingTuesday participation, and Community Impact Days. In 2024, McKesson employees raised the bar in community service, making differences in the communities where they live, work, and serve, with Biologics staff contributing to these efforts.

Responsible Pharmacy Practices: The company maintains high ethical standards in pharmaceutical dispensing, patient privacy protection, and regulatory compliance. Biologics by McKesson follows strict protocols for controlled substance handling, prescription verification, and patient education that support responsible medication use and prevent diversion.

Healthcare Equity: Biologics by McKesson addresses healthcare equity by providing specialized pharmacy services to patients with complex conditions who might otherwise face barriers to care. The company's focus on oncology and rare diseases serves populations with significant healthcare needs, contributing to more equitable access to specialized treatments.

Employee Development: The company invests in sustainable workforce development through continuous education and training programs for pharmacy staff, ensuring high-quality patient care while creating long-term career opportunities in the specialty pharmacy field.

Biologics by McKesson has achieved significant recognition for specialty pharmacy excellence, accreditation achievements, and leadership in oncology and rare disease pharmacy services, establishing itself as a trusted healthcare partner.

URAC Specialty Pharmacy Accreditation: Biologics, Inc. achieved prestigious Specialty Pharmacy accreditation from URAC, the healthcare industry's leading certification and accreditation organization that evaluates quality standards. This accreditation demonstrates Biologics by McKesson's commitment to maintaining high standards in specialty pharmacy operations and patient care delivery.

NASP Premier Event Sponsorship: Biologics by McKesson was selected as an Onyx level sponsor for the 2024 NASP (National Association of Specialty Pharmacy) Annual Meeting & Expo, the premier specialty pharmacy event of the year. This sponsorship level recognizes Biologics' leadership position in the specialty pharmacy industry and its commitment to advancing the field.

CMS Qualified Clinical Data Registry: For the ninth consecutive year in 2025, the Centers for Medicare & Medicaid Services (CMS) named McKesson's Practice Insights as a Qualified Clinical Data Registry. This designation enables providers to report meaningful, oncology-specific quality measures for participation in the Merit-based Incentive Payment System, reflecting the company's contributions to healthcare quality improvement.

Industry Leadership Recognition: Biologics by McKesson has been acknowledged for its three decades of leadership in oncology pharmacy services, with particular recognition for its work in bringing oncology therapies to market through partnerships with biopharma companies. The company's seasoned specialty pharmacy team possesses in-depth understanding of patient care and treatment access.

Patient Care Excellence: The company has received recognition for its advanced care model specifically designed to meet the clinical, financial, and emotional needs of cancer patients. Unlike traditional retail pharmacies, Biologics by McKesson offers comprehensive support services that address the complex requirements of oncology and rare disease treatments.

Community Impact Recognition: Biologics by McKesson's involvement in McKesson Amplify, a strategic initiative to strengthen independent community pharmacies, has been recognized for its positive impact on pharmacy advocacy, education, and outreach programs that support healthcare access at the community level.

Biologics by McKesson operates within the context of McKesson Corporation's broader legal and regulatory challenges, particularly regarding opioid distribution practices, though the specialty pharmacy division itself maintains a strong operational record.

McKesson Opioid Settlement: In January 2021, McKesson Corporation agreed to pay a record $150 million civil penalty for alleged violations of the Controlled Substances Act related to failure to report suspicious orders of painkillers. The Justice Department alleged that from 2008 to 2013, McKesson supplied various U.S. pharmacies with increasing amounts of oxycodone and hydrocodone pills frequently misused in the opioid epidemic. The settlement included suspensions of controlled substance sales from distribution centers in Colorado, Ohio, Michigan, and Florida.

Previous Compliance Issues: This was not McKesson's first violation; the company faced similar accusations in 2008 and paid $13.25 million to settle that case. McKesson was supposed to enact tougher measures to identify and prevent suspicious orders but failed to do so adequately, leading to the more severe penalty in 2021.

Regulatory Monitoring: The settlement required McKesson to implement enhanced monitoring systems and halt controlled substance sales from affected distribution centers for multiple years. While these issues primarily concern McKesson's wholesale distribution business rather than the Biologics specialty pharmacy division, they reflect on the parent company's overall compliance record.

Specialty Pharmacy Operations: Biologics by McKesson itself has not experienced major operational controversies or recalls. The specialty pharmacy division maintains strong regulatory compliance in its handling of oncology and rare disease medications, with no reported issues related to medication errors, patient safety, or pharmacy practice violations.

Patient Care Focus: Despite parent company challenges, Biologics by McKesson has maintained its focus on providing high-quality patient care services. The specialty pharmacy's dedication to oncology and rare disease patients has helped it maintain a positive reputation within the healthcare community and among patient populations.

Ongoing Compliance: Biologics by McKesson operates under enhanced compliance protocols implemented across McKesson Corporation following the opioid settlement, ensuring that all pharmacy operations meet or exceed regulatory requirements for controlled substance handling and patient care standards.